Raloxifene

Raloxifene belongs to the family of selective estrogen receptor modulators, the SERMs. Its distinctive feature lies in that word, selective: depending on the tissue, it behaves differently at the estrogen receptor. In bone, it acts as an agonist, meaning that it mimics estrogen. In the uterus and the breast, by contrast, it behaves as an antagonist, blocking the receptor.

This dual action explains its place in postmenopausal women. In bone, it slows bone resorption, the stage where old bone is broken down, and it reduces the biochemical markers of remodeling. The result can be measured: bone mineral density increases. Raloxifene does not build new bone, it slows the loss of it.

Raloxifene follows an unusual metabolic path. It is not transformed by the cytochrome P450 enzymes, the liver enzymes responsible for breaking down many medications. Instead, it undergoes extensive glucuronide conjugation: the liver and the intestine attach glucuronide molecules to it to make it soluble. This particular pathway limits the CYP-type interactions that are common with other treatments.

Its pharmacokinetics also explain why a once-daily dose is enough. Raloxifene and its glucuronides continually interconvert through reversible metabolism and an enterohepatic cycle, a back-and-forth between the liver and the intestine. This recycling extends the elimination half-life to 27.7 hours. Absolute bioavailability remains low, around 2 percent, and raloxifene circulates 95 percent bound to plasma proteins.

Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. After menopause, the drop in estrogen accelerates bone loss and weakens the skeleton. By mimicking estrogen in bone, raloxifene partly makes up for this loss of protection and reduces the risk of vertebral fracture.

It has a second indication, tied to its antagonist action in the breast: reducing the risk of invasive breast cancer in certain postmenopausal women at high risk. The choice between raloxifene and other osteoporosis treatments depends on each woman’s profile, on her bone and vascular risk factors, and is decided together with the physician.

The dosing is simple: one 60 mg tablet by mouth, once a day. You can take it at any time of day, with or without food, which leaves plenty of freedom to fit it into a routine. Consistency matters more than timing: a steady daily dose maintains the effect on bone.

Raloxifene acts on bone but does not correct a deficiency in calcium or vitamin D. If your dietary intake is insufficient, a calcium and vitamin D supplement is recommended in addition to the treatment. Like any osteoporosis treatment, it should not be stopped on your own initiative: bone loss resumes as soon as it is stopped, and that decision rests with the physician.

Hot flashes affect 9.7 percent of women taking raloxifene 60 mg, compared with 6.4 percent on placebo. Leg cramps affect 7.0 percent of women, compared with 3.7 percent on placebo. Flu-like syndrome is reported in 13.5 percent, compared with 11.4 percent on placebo, and peripheral edema in 5.2 percent, compared with 4.4 percent.

The important risk to know about is vascular. Raloxifene increases the risk of venous thromboembolism, roughly 1 case per 100 treated patients: in the MORE trial, 26 cases on raloxifene versus 11 on placebo, giving a hazard ratio of 2.4 (95 percent confidence interval of 1.2 to 4.5). A boxed warning flags this risk of deep vein thrombosis and pulmonary embolism, as well as an increased risk of death from stroke in women with coronary heart disease or at high risk of it.

Some situations rule out raloxifene. It is contraindicated in case of a history or an active episode of venous thromboembolism, and during pregnancy or breastfeeding. A planned long trip spent sitting still or a hospital stay with bed rest is worth mentioning to the physician, because such situations raise the venous risk.

Two interactions call for caution. Cholestyramine, a drug that binds bile acids, reduces the absorption and the enterohepatic cycle of raloxifene: the two should not be taken together. With warfarin, an anticoagulant, raloxifene can alter prothrombin time, a measure of coagulation that then needs to be monitored. Follow-up of the treatment combines measuring bone density over time with attention to these vascular signals.